Cargando…

Model‐based prediction of progression‐free survival for combination therapies in oncology

Progression‐free survival (PFS) is an important clinical metric for comparing and evaluating similar treatments for the same disease within oncology. After the completion of a clinical trial, a descriptive analysis of the patients' PFS is often performed post hoc using the Kaplan–Meier estimato...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baaz, Marcus, Cardilin, Tim, Jirstrand, Mats
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10508530/ https://www.ncbi.nlm.nih.gov/pubmed/37300376 http://dx.doi.org/10.1002/psp4.13003

Ejemplares similares

Model-based assessment of combination therapies – ranking of radiosensitizing agents in oncology
por: Baaz, Marcus, et al.
Publicado: (2023)

Optimized scaling of translational factors in oncology: from xenografts to RECIST
por: Baaz, Marcus, et al.
Publicado: (2022)

Model‐Based Evaluation of Radiation and Radiosensitizing Agents in Oncology
por: Cardilin, Tim, et al.
Publicado: (2017)

Exposure-response modeling improves selection of radiation and radiosensitizer combinations
por: Cardilin, Tim, et al.
Publicado: (2021)

Modeling long-term tumor growth and kill after combinations of radiation and radiosensitizing agents
por: Cardilin, Tim, et al.
Publicado: (2019)

A method for zooming of nonlinear models of biochemical systems
por: Sunnåker, Mikael, et al.
Publicado: (2011)

Quantifying the association between progression‐free survival and overall survival in oncology trials using Kendall's τ
por: Weber, Enya M., et al.
Publicado: (2018)

Progression-free survival as a surrogate for overall survival in oncology trials: a methodological systematic review
por: Belin, Lisa, et al.
Publicado: (2020)

Modeling of free fatty acid dynamics: insulin and nicotinic acid resistance under acute and chronic treatments
por: Andersson, Robert, et al.
Publicado: (2017)

Community-driven development of a modified progression-free survival ratio for precision oncology
por: Mock, Andreas, et al.
Publicado: (2019)

Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology
por: Hess, Lisa M, et al.
Publicado: (2019)

Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials
por: Wang, Zi-Xian, et al.
Publicado: (2021)

A New Method to Model and Predict Progression Free Survival Based on Tumor Growth Dynamics
por: Yu, Jiajie, et al.
Publicado: (2020)

Challenge model of TNF(α) turnover at varying LPS and drug provocations
por: Held, Felix, et al.
Publicado: (2019)

Predictive Power of MIB-1 vs. Mitotic Count on Progression-Free Survival in Skull-Base Meningioma
por: Lampmann, Tim, et al.
Publicado: (2022)

Correction: Community-driven development of a modified progression-free survival ratio for precision oncology
Publicado: (2020)

A stochastic mixed effects model to assess treatment effects and fluctuations in home‐measured peak expiratory flow and the association with exacerbation risk in asthma
por: Leander, Jacob, et al.
Publicado: (2021)

Using sensitivity equations for computing gradients of the FOCE and FOCEI approximations to the population likelihood
por: Almquist, Joachim, et al.
Publicado: (2015)

Mixed Effects Modeling Using Stochastic Differential Equations: Illustrated by Pharmacokinetic Data of Nicotinic Acid in Obese Zucker Rats
por: Leander, Jacob, et al.
Publicado: (2015)

Modelling of oscillatory cortisol response in horses using a Bayesian population approach for evaluation of dexamethasone suppression test protocols
por: Held, Felix, et al.
Publicado: (2019)

Predicting progression-free survival after systemic therapy in advanced head and neck cancer: Bayesian regression and model development
por: Barber, Paul R, et al.
Publicado: (2022)

A continuous-time adaptive particle filter for estimations under measurement time uncertainties with an application to a plasma-leucine mixed effects model
por: Krengel, Annette, et al.
Publicado: (2013)

Multi-Parameter MR Radiomics Based Model to Predict 5-Year Progression-Free Survival in Endometrial Cancer
por: Liu, Defeng, et al.
Publicado: (2022)

MRI radiomics predicts progression-free survival in prostate cancer
por: Jia, Yushan, et al.
Publicado: (2022)

Zooming of states and parameters using a lumping approach including back-translation
por: Sunnåker, Mikael, et al.
Publicado: (2010)

Association between progression-free survival and health-related quality of life in oncology: a systematic review protocol
por: Kovic, Bruno, et al.
Publicado: (2016)

Oncological Patients With Endocrine Complications After Immunotherapy With Checkpoint Inhibitors Present Longer Progression-Free and Overall Survival
por: Paschou, Stavroula A., et al.
Publicado: (2022)

Plasma Pharmacokinetics of N-Acetylgalactosamine-Conjugated Small-Interfering Ribonucleic Acids (GalNAc-Conjugated siRNAs)
por: Sten, Sebastian, et al.
Publicado: (2023)

A Nonlinear Mixed Effects Approach for Modeling the Cell-To-Cell Variability of Mig1 Dynamics in Yeast
por: Almquist, Joachim, et al.
Publicado: (2015)

Corrigendum: MRI radiomics predicts progression-free survival in prostate cancer
por: Jia, Yushan, et al.
Publicado: (2023)

Impact of tumour volume on prediction of progression-free survival in sinonasal cancer
por: Hennersdorf, Florian, et al.
Publicado: (2015)

Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival
por: Lazar, Vladimir, et al.
Publicado: (2021)

Methods of Cut-Elimination
por: Baaz, Matthias, et al.
Publicado: (2011)

Predicting Progression-Free Survival Using MRI-Based Radiomics for Patients With Nonmetastatic Nasopharyngeal Carcinoma
por: Shen, Hesong, et al.
Publicado: (2020)

CT-Based Radiomics Nomogram for Prediction of Progression-Free Survival in Locoregionally Advanced Nasopharyngeal Carcinoma
por: Yan, Chang, et al.
Publicado: (2021)

Model-based meta-analysis of progression-free survival in non-Hodgkin lymphoma patients
por: Li, Mengyao, et al.
Publicado: (2017)

Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL
por: Mikhaeel, N. George, et al.
Publicado: (2016)

Immuno-oncology combinations: raising the tail of the survival curve
por: Harris, Samuel J., et al.
Publicado: (2016)

Deep learning prediction of pathological complete response, residual cancer burden, and progression-free survival in breast cancer patients
por: Dammu, Hongyi, et al.
Publicado: (2023)

Chimeric Antigen Receptor T-cell Therapy: Imaging Response Criteria and Relation to Progression-free and Overall Survival
por: Winkelmann, Michael, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p2cn06pf8dln7lljs5gpgcn9iv